Featured Research

from universities, journals, and other organizations

Prolonged Overall Survival For Patients With Acute Myeloid Leukemia

Date:
December 10, 2008
Source:
MDS Foundation
Summary:
Patients with acute myeloid leukemia who were treated with vidaza (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens.

The Myelodysplastic Syndromes (MDS) Foundation has announced that data presented at this year's American Society of Hematology (ASH) Meeting in San Francisco demonstrate that patients with acute myeloid leukemia (AML) who were treated with VIDAZA (azacitidine) had significantly increased overall survival compared to those treated with conventional care regimens (CCR).

Related Articles


AML is a cancer of myeloid blood cells where abnormal cells accumulate in the bone marrow and interfere with normal blood cell production. Patients with AML typically have a poor prognosis and do not respond well to conventional chemotherapy. Roughly 30 percent of patients diagnosed with MDS will progress to AML.

Dr. Pierre Fenaux, of the University of Paris, presented the updated results from an international phase III trial (AZA-001) which was the first study to show an increased overall survival for higher-risk MDS patients. One-third of patients enrolled in the trial met the World Health Organization (WHO) criteria for AML. This analysis showed that 50 percent of the AML patients who were treated with VIDAZA survived at least two years, compared to only 16 percent of patients treated with CCR.

"The data presented at this year's ASH Meeting are encouraging for both physicians and patients and demonstrate the major advancements that have been made in treating hematologic conditions, like MDS and AML, over the past several years," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation, "We are hopeful about the potential of novel therapies, like VIDAZA, which are helping patients to live longer with a better quality of life."

The data presented today are a follow-up to results from the AZA-001 trial presented at the American Society of Clinical Oncology Meeting in June, which showed that patients with high-risk MDS who received VIDAZA had higher one-year survival rates in all response categories, including partial remission, stable disease and hematologic improvement, compared to those who received CCR without necessarily achieving complete remission.

About MDS

MDS is a cancer in which the bone marrow fails to make enough functioning blood cells, either red blood cells, white blood cells or platelets. It is not known exactly how many people have MDS, however, about 20,000 to 25,000 new cases are diagnosed annually in the U.S. In addition, roughly 30 percent of patients diagnosed with MDS will progress to acute myeloid leukemia (AML).


Story Source:

The above story is based on materials provided by MDS Foundation. Note: Materials may be edited for content and length.


Cite This Page:

MDS Foundation. "Prolonged Overall Survival For Patients With Acute Myeloid Leukemia." ScienceDaily. ScienceDaily, 10 December 2008. <www.sciencedaily.com/releases/2008/12/081210180856.htm>.
MDS Foundation. (2008, December 10). Prolonged Overall Survival For Patients With Acute Myeloid Leukemia. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2008/12/081210180856.htm
MDS Foundation. "Prolonged Overall Survival For Patients With Acute Myeloid Leukemia." ScienceDaily. www.sciencedaily.com/releases/2008/12/081210180856.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
Toxin-Packed Stem Cells Used To Kill Cancer

Toxin-Packed Stem Cells Used To Kill Cancer

Newsy (Oct. 25, 2014) — A Harvard University Research Team created genetically engineered stem cells that are able to kill cancer cells, while leaving other cells unharmed. Video provided by Newsy
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins